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Abstract
The proangiogenic cytokine Interleukin-3 (IL-3) is released by inflammatory cells in breast and ovarian cancer tissue
microenvironments and also acts as an autocrine factor for human breast and kidney tumor-derived endothelial cells (TECs).
We have previously shown that IL-3-treated endothelial cells (ECs) release extracellular vesicles (EVs), which serve as a
paracrine mechanism for neighboring ECs, by transferring active molecules. The impact of an anti-IL-3R-alpha blocking
antibody on the proangiogenic effect of EVs released from TECs (anti-IL-3R-EVs) has therefore been investigated in this
study. We have found that anti-IL-3R-EV treatment prevented neovessel formation and, more importantly, also induced the
regression of in vivo TEC-derived neovessels. Two miRs that target the canonical wingless (Wnt)/β-catenin pathway, at
different levels, were found to be differentially regulated when comparing the miR-cargo of naive TEC-derived EVs (EVs)
and anti-IL-3R-EVs. miR-214-3p, which directly targets β-catenin, was found to be upregulated, whereas miR-24-3p, which
targets adenomatous polyposis coli (APC) and glycogen synthase kinase-3β (GSK3β), was found to be downregulated. In
fact, upon their transfer into the cell, low β-catenin content and high levels of the two members of the “β-catenin destruction
complex” were detected. Moreover, c-myc downregulation was found in TECs treated with anti-IL-3R-EVs, pre-miR-214-
3p-EVs and antago-miR-24-3p-EVs, which is consistent with network analyses of miR-214-3p and miR-24-3p gene
targeting. Finally, in vivo studies have demonstrated the impaired growth of vessels in pre-miR-214-3p-EV- and antago-
miR-24-3p-EV-treated animals. These effects became much more evident when combo treatment was applied. The results of
the present study identify the canonical Wnt/β-catenin pathway as a relevant mechanism of TEC-derived EV proangiogenic
action. Furthermore, we herein provide evidence that IL-3R blockade may yield some significant advantages, than miR
targeting, in inhibiting the proangiogenic effects of naive TEC-derived EVs by changing TEC-EV-miR cargo.
Introduction
Interleukin-3 (IL-3) was originally described as a potent
hemopoietic growth factor which acts on progenitor/stem
cells and on mature cells [1, 2]. However, the involvement
of IL-3 in vascular cell proliferation and activation during
physiological and tumor angiogenesis has been extensively
documented [3–7]. T lymphocytes and mast cells are the
most relevant IL-3-producing cells [8, 9]. Moreover, ovar-
ian and breast cancer-derived tumor infiltrating lympho-
cytes (CD25/CD4/CD5+TILs) express IL-3 [10]. As
originally reported by Deregibus et al. [11], IL-3 also acts as
an autocrine factor for tumor-derived endothelial cells
(TECs). These data have been further validated in human
breast and kidney TECs [12]. Overall, IL-3, present in the
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Fig. 1 Internalization and proliferation in response to TEC-derived EVs
and anti-IL-3R-EVs. a Number of EV particles (mean± SD) was cal-
culated per ml. Data refer to EV-derived from untreated TECs (EVs) or
anti-IL-3Rα blocking antibody-treated TECs (anti-IL-3R-EVs) (n= 4,
unpaired t-test). b Representative images of NanoSight analyses per-
formed on the 100 k fraction of TEC-derived EVs, showing a mean
dimension, for both EVs, of 169 nm (n= 3). c TEC-derived EVs were
analyzed for CD63 and CD81 exosomal markers by western blot
analysis (n= 4, unpaired t-test). d Representative confocal microscopy
images of TECs, either untreated or treated for 3 h with the indicated
PKH26-labeled EVs, to evaluate EV up-take TECs. (n= 4). Scale bars
indicate 10 μm (40× magnification). e Cell proliferation assay was
performed in TECs untreated (none) or treated for 24 h with EVs or
anti-IL-3R-EVs and reported as number of cells per field (mean± SD,
20× magnification) (n= 5) (***p< 0.001, none vs EVs; ***p< 0.001,
none and EVs vs anti-IL-3R-EVs, one-way ANOVA). f TECs, either
alone or stimulated with EVs or anti-IL-3R-EVs, were lysed and ana-
lyzed for cyclin D1 content. Protein levels were normalized to β-actin
content (**p< 0.01, none vs anti-IL-3R-EVs; ***p< 0.001, EVs vs
anti-IL-3R-EVs, one-way ANOVA) (n= 4)
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tumor microenvironment, can contribute to tumor growth
via paracrine and autocrine mechanisms.
The classic paracrine signaling paradigm has been re-
evaluated somewhat since it was discovered that both
cancer and tumor microenvironment cells generate
membrane-enclosed packets, called extracellular vesicles
(EVs). EVs from different origin contain both a common set
of molecules and components specific of the cell of origin.
EVs released from cancer cells contain proteins reflecting
their endosomal origin together with cellular oncogenic
drivers, phosphorylated proteins and miRNAs [13–15]. EVs
have also received increasing levels of attention in recent
years because of their role in regulating and transferring
active molecules that are responsible for tumor metastasis
[16]. Therefore, to inhibiting EV functional effects would
most likely yield some significant advantages in the treat-
ment of neoplasm. Unlike soluble factors secreted by cells,
EVs bring functional molecules, which serve as intra- and
intercellular communicators, locally and systemically [17].
EVs can promote tumor growth and metastasis even by
inducing angiogenesis [13–16, 18–20]. This event has been
extensively documented in tumor cell-derived EVs [21].
However, endothelial cells (ECs) themselves can release
EVs in response to angiogenic stimuli [22] thus also con-
tributing to the angiogenic activity of growing microvessels.
Several studies have described the Wnt-β-catenin pathway
as a crucial regulator of EC fate during embryonic devel-
opment and tumor angiogenesis [23–28]. Unlike in normal
mature cells, the abnormal activation of the Wnt/β-catenin
signal occurs during cancer development [24, 25, 29–31].
The canonical Wnt/β-catenin signaling pathway initiates by
the binding of the Wnt ligand to its receptor, Frizzled (FZD),
and the LDL receptor-related proteins 5 or 6 [29, 32–34]. As
a consequence, the cytoplasmic protein Disheveled (Dvl) is
phosphorylated and the detachment of β-catenin from the “β-
Catenin destruction complex”, which consists of a number of
members including the adenomatous polyposis coli (APC),
Axin the glycogen synthase kinase-3β (GSK3β) and the
casein kinase 1α (CK1), is enabled [29,32–34]. Stabilized β-
catenin translocates into the nucleus where it forms a β-
catenin-T-cell factor/lymphoid enhancer factor (TCF/LEF)
transcriptional complex and induces the transcription of some
of its downstream genes, such as c-myc and cyclin D1 [29,
32–34]. In the absence of Wnt, cytoplasmic β-catenin is
phosphorylated by activated GSK3β and undergoes protea-
somal degradation [29, 32–34]. The role of Wnt/β-catenin in
driving carcinogenesis, cancer progression and metastasis has
been extensively documented in many tumors [24, 25, 29–
31] Furthermore, evidence to support the relevance of the
interaction between miRs and the Wnt/β-catenin pathway in
cancer has recently emerged [24, 35]. However, the con-
tribution of miRs to regulating the Wnt/β-catenin signaling
pathway in tumor angiogenesis has only been poorly
investigated.
We have recently provided evidence that EC-derived
EVs mediate the transfer of activated proteins and miRs in
inflammatory sites containing IL-3, which boosts wound
healing [22]. These observations have led us to hypothesize
that the release of IL-3 by TECs may also support the
establishment of a favorable milieu via EVs. In this study,
we have therefore decided to investigate the proangiogenic
action of TEC-derived EVs and the impact of an anti-IL-3R-
alpha blocking antibody, which is currently under investi-
gation in acute myeloid leukemia patients [36], on the
proangiogenic effect of EVs released from TECs.
Results
EVs released by TECs subjected to IL-3 receptor
blockade reduce TEC proliferation
It has been reported that ECs, when subjected to IL-3, release
EVs which act as paracrine proangiogenic mediators [22]. To
investigate whether and how TEC-derived EVs induce
proangiogenic cues and whether this effect may be prevented
by interfering with IL-3-mediated signaling, EVs were
recovered after treating TECs with an antibody against
the IL-3 receptor alpha subunit (anti-IL-3R-EVs). Firstly, we
investigated whether differences in EV release occurred. No
differences in the number (Fig. 1a) and size (Fig. 1b) of EVs
released were found. Exosome expression markers are
reported in Fig. 1c. In order to evaluate whether EVs released
under both experimental conditions could be internalized to
act as paracrine mediators, EVs labeled with PKH26 dye
were assayed for TEC internalization. Figure 1d shows that
both EVs and anti-IL-3R-EVs can be incorporated by TECs.
To exclude the possibility that the anti-IL-3R antibody bound
to EVs could mediate the effects of anti-IL-3R-EVs, Western
blot analysis was performed on anti-IL-3R EV pellet and
anti-IL-3R-EV-depleted conditioned medium (CM). Supple-
mentary Fig. 1a-b clearly demonstrated the presence of the
anti-IL-3R antibody in the anti-IL-3R-EV-depleted CM, but
not in the anti-IL-3R-EV pellets. EV-depleted CM and EV
pellet from untreated TECs served as controls. Functional
studies were also performed by exploring the effect that EVs
and anti-IL-3R-EVs had on TEC proliferation. Unstimulated
TECs were used as an internal control. It was found that EVs
promoted TEC proliferation, as shown in Fig. 1e. This effect
was significantly reduced in TECs treated with anti-IL-3R-
EVs. Low cyclin D1 levels were consistently detected in
TECs that had been stimulated with anti-IL-3R-EVs (Fig. 1f).
No differences in the number of apoptotic cells were found
(data not shown).
IL-3Rα blockade inhibits EV-mediated tumor angiogenesis
Fig. 2 Anti-IL-3R-EVs impair vessel formation. a, b Representative
photomicrographs of an in vitro angiogenesis assay, showing tube-like
structure formation by TECs, either untreated or treated with 7× 103/
cell EVs or anti-IL-3R-EVs. Data are reported in the histogram as
number± SD of tubular structures per field (**p< 0.01, none and EVs
vs anti-IL-3R-EVs, one-way ANOVA) (n= 4, 10× magnification).
Scale bars indicate 100 μm. c, d Representative images of an in vivo
angiogenesis assay, performed by injecting Matrigel matrices con-
taining either 1× 106 TECs and 1× 105/cell of EVs or anti-IL-3R-EVs
into the flank of SCID mice. Saline was the internal control. As shown
by the timeline, plugs were recovered on day 7 after implantation. Data
are reported in the histogram as number ± SD of vessels per sample
(**p< 0.01, none vs anti-IL-3R-EVs; ***p< 0.001, EVs vs anti-IL-
3R-EVs, one-way ANOVA) (20× magnification). Scale bars indicate
50 μm. e, f Representative images of an in vivo angiogenesis assay to
evaluate the ability of anti-IL-3R-EVs to impair the growth of tumor
vessels. The timeline and the endpoint are indicated. Data are reported
in the histogram as number ± SD of vessels per sample (**p< 0.01,
none and EVs vs anti-IL-3R-EVs, one-way ANOVA) (20× magnifi-
cation). Scale bars indicate 50 μm
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IL-3Rα blockade inhibits EV-mediated tumor angiogenesis
Anti-IL-3R-EVs prevent and impair the growth of
tumor vessels
An in vitro angiogenic assay was performed in order to
evaluate whether anti-IL-3R-EVs interfere with TECs’
ability to form neovessels. The treatment of TECs with anti-
IL-3R-EVs was associated with reduced formation of tube-
like structures, as shown in Fig. 2a, b. Two different in vivo
approaches were used to confirm this effect. TECs, pre-
incubated with EVs and anti-IL-3R-EVs, were included in
Matrigel and injected subcutaneously into severe combined
immunodeficient (SCID) mice. 7 days after implantation,
plugs were recovered and analyzed for the presence of
vessels. As shown in Fig. 2c, d, anti-IL-3R-EVs almost
completely inhibited the angiogenetic capability of TECs.
In order to evaluate whether anti-IL-3R-EVs could also be
exploited as a therapeutic option, in vivo experiments were
performed by injecting Matrigel-containing TECs into
SCID mice. Either EVs, anti-IL-3R-EVs or saline were
administered locally on days 3 and 7 after implantation. The
plugs were recovered and analyzed on day 10. It was found
that mice treated with anti-IL-3R-EVs failed to form orga-
nized vessels in vivo, unlike saline- or EV-treated animals,
as shown in Fig. 2e, f. These results indicate that anti-IL-
3R-EVs are active in preventing and impairing the growth
of tumor neovessels.
Anti-IL-3R-EV-mediated biological effects depend on
their miR cargo variation
EV biological activity relies on the transfer into recipient
cells of proteins, lipids and genetic material, including
miRs, [13, 14, 17, 37–39]. Anti-IL-3R-EV miR content was
therefore compared to that of EVs in order to investigate the
molecular mechanisms that account for in vivo results. A
complete panel of mature miRs was screened. Figure 3a, b
shows the distribution of miRs that were upregulated and
downregulated in anti-IL-3R-EVs. miR fold change is
reported in Supplementary Tables 1 and 2. Software pre-
diction analyses on modulated miRs in anti-IL-3R-EV cargo
identified two miRs that were differentially modulated and
that shared a common pathway; the canonical Wnt-β-
catenin pathway. These miRs were found to act on different
levels; miR-214-3p, which is upregulated, directly targets β-
catenin [40], miR-24-3p, which is downregulated, targets
two different “β-catenin destruction complex” genes, APC
and GSK3β (TarBase v7.0) [41]. The expression of miR-24-
3p and miR-214-3p in EVs and anti-IL-3R-EVs was vali-
dated by real-time PCR (Fig. 3c). It was then decided to
analyze the expression of phosphorylated and unpho-
sphorylated β-catenin in total cell lysates in TECs treated
with EVs and anti-IL-3R-EVs in order to investigate the
possibility that miR-24-3p and miR-214-3p, carried by anti-
IL-3R-EVs, may interfere with the β-catenin signaling
pathway. The results reported in Fig. 3d clearly only
demonstrate an increase in phosphorylated, and a decrease
in unphosphorylated β-catenin content in TECs subjected to
anti-IL-3R-EV treatment. Supplementary Fig. 2a, b show
that, in TECs, the level of phosphorylated and unpho-
sphorylated β-catenin did not change upon anti-IL-3R
treatment.
The canonical Wnt/β-Catenin pathway is targeted by
anti-IL-3R-EVs
APC and GSK3β, known miR-24-3p targets, were eval-
uated to gain further insight into the anti-IL-3R-EV
mechanism of action. As shown in Fig. 3e, both APC and
GSK3β levels increased after anti-IL-3R-EV treatment.
Conversely, their expression did not change in anti-IL-
3R-treated TECs (Supplementary Fig. 2b). APC and
GSK3β were neither detected in naive nor in anti-IL-3R-
EVs (Supplementary Fig. 2b). β-catenin was strongly
reduced in the nuclear fraction (Fig. 3f), which is con-
sistent with the increase in “β-catenin destruction com-
plex” components. This was further validated by
immunoprecipitation experiments using an antibody
against the beta-transducing repeats-containing proteins
(β-TrCP), which act as the substrate recognition subunits
for the SCF (Skp1–Cullin1–Fbox protein)β-TrCP E3
Fig. 3 Anti-IL-3R-EV miR distribution and modulation of the β-
catenin signaling pathway upon EV and anti-IL-3R-EV treatment a
Dot plot graph distribution of the 47 significant upregulated miRs in
anti-IL-3R-EVs, compared to EVs. Each dot represents the fold change
value of each miR. Only miRs with fold change ≥ 2 are reported. miR-
214-3p (red dot) was found as the most upregulated miR in anti-IL-3R-
EVs (fold change: 93.63± 4.52). b Dot plot graph distribution of the
107 significant downregulated miRs in anti-IL-3R-EVs, compared to
EVs. miRs with fold change ≤ 2 are reported. miR-24-3p (red dot) was
found to be downregulated (fold change: -2.17± 0.08). c miR‐24-3p
and miR-214-3p expression was validated by qRT–PCR on EVs and
anti-IL-3R-EVs and data normalized to RNU6B (n= 4) (**p< 0.01,
EVs vs anti-IL-3R-EVs for miR‐24-3p and miR-214-3p, unpaired t-
test). d Total cell extracts from TECs, treated as indicated, were
subjected to Western blot analysis to evaluate pβ-catenin and β-catenin
content, normalized to β-actin (n= 4) (**p< 0.01 none and EVs vs
anti-IL-3R-EVs for pβ-catenin; **p< 0.01 none vs EVs for β-catenin;
***p< 0.001 EVs vs anti-IL-3R-EVs for β-catenin, one-way
ANOVA). e Cytoplasmic extracts from TECs, treated as indicated,
were subjected to Western blot analysis to evaluate APC and GSK 3β
content, normalized to β-actin (n= 4) (**p< 0.01, none and EVs vs
anti-IL-3R-EVs, one-way ANOVA). f Nuclear extracts from TECs,
treated as above, were analyzed for β-catenin content and normalized
to H3 (n= 3) (**p< 0.01, none and EVs vs anti-IL-3R-EVs, one-way
ANOVA). g Cytoplasmic extracts from untreated or treated TECs, as
indicated, were immunoprecipitated with anti-β-TrCP antibody, sub-
jected to SDS–PAGE and immunoblotted with anti-β-catenin and anti-
β-TrCP antibodies (***p< 0.001, none and EVs vs anti-IL-3R-EVs,
one-way ANOVA)
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ubiquitin ligases [42]. Indeed, a complex containing the
phosphorylated β-catenin and β-TrCP was detected upon
anti-IL-3R-EV treatment (Fig. 3g). Since β-catenin
content was reduced in the total lysates of anti-IL-3R-
EV-treated TECs (Fig. 3d), it was decided to determine
whether the enrichment of miR-214-3p in anti-IL-3R-
Fig. 4 EV miR content controls
β-catenin activation. a TECs that
over-express miR-214-3p were
subjected to SDS–PAGE to
evaluate β-catenin content,
normalized to β-actin.
Untransfected TECs were used
as internal controls (none) (n=
5) (**p< 0.01, none vs pre-
miR-214-3p, unpaired t-test). b
Cell extracts from TECs, left
untreated or treated with EVs,
anti-IL-3R-EVs or EVs enriched
in miR-214-3p, were analyzed
for β-catenin content,
normalized to β-actin (n= 5)
(**p< 0.01, none and EVs vs
anti-IL-3R-EVs and pre-miR-
214-3p-EVs, one-way
ANOVA). c, d Cytoplasmic
extracts from TECs depleted of
miR-24-3p (antago-miR-24-3p)
(c) and from TECs treated with
antago-miR-24-3p-EVs (d) were
analyzed by Western blot for
APC and GSK3β content (**p
< 0.01, none vs antago-miR-24-
3p in (c), unpaired t-test, and
**p< 0.01, EVs vs anti-IL-3R-
EVs and antago-miR-24-3p-EVs
in d, one-way ANOVA). e, f
Cell extracts from antago-miR-
24-3p TECs (e) and from TECs,
treated as above (f), were
analyzed for pβ-catenin and β-
catenin content, normalized to β-
actin (n= 4) (*p< 0.05, for pβ-
catenin and **p< 0.01, for β-
catenin, none vs antago-miR-24-
3p in e, unpaired t-test, and **p
< 0.01, none and EVs vs anti-
IL-3R-EVs and antago-miR-24-
3p-EVs in f, one-way ANOVA)
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EVs could exert a direct β-catenin expression effect.
Gain-of-function experiments were therefore performed.
TECs were transfected with pre-miR-214-3p and EVs
were recovered (pre-miR-214-3p-EVs). Transfection
efficacy was confirmed by real-time PCR (rt-PCR) in
both cells and EVs (Supplementary Fig. 3a, b). The
effects of pre-miR-214-3p on β-catenin expression were
initially evaluated in transfected cells (Fig. 4a) and then
in TECs treated with pre-miR-214-3p-EVs (Fig. 4b). As
expected, β-catenin content was reduced both in trans-
fected cells and in TECs stimulated with pre-miR-214-
3p-EVs. The contribution of miR-24-3p to anti-IL-3R-
EV-mediated action was then evaluated by performing
loss-of-function experiments. TECs were transfected with
antago-miR-24-3p and EVs (antago-miR-24-3p-EVs)
were recovered. Antago-miR-24-3p depletion was con-
firmed by rt-PCR in cells and EVs (Supplementary
Fig. 1c, d). As shown in Fig. 4c, d, increased APC and
GSK3β content was detected in both transfected cells and
in antago-miR-24-3p-EV-treated TECs. Furthermore,
increased levels of phosphorylated β-catenin and a
decrease in unphosphorylated β-catenin were found
(Fig. 4e, f). The integrated miR-24-3p and miR-214-3p
interaction-network identified c-myc as one of their
downstream nodes (Fig. 5a). c-myc expression was
therefore analyzed on TECs treated with different EVs.
As shown in Fig. 5b, anti-IL-3R-EVs, antago-miR-24-3p-
and pre-miR-214-3p-EVs failed to induce c-myc
expression, unlike EVs.
miR-214-3p and miR-24-3p are both involved in
anti-IL-3R-EV-antiagiogenic effects
Functional studies were performed in vivo to confirm the above
data. Differing EV sources were used to treat mice on day 3 and
7 after TEC injection. As shown in Fig. 6a, b, both pre-miR-
214-3p-EVs and antago-miR-24-3p-EVs strongly reduced
TEC-derived vessels in vivo. However, it was found that, unlike
antago-miR-24-3p-EVs, pre-miR-214-3p-EVs were less effec-
tive in reducing vessel growth than anti-IL-3R-EVs, while the
combo treatment completely recapitulated the anti-IL-3R-EV
anti-angiogenic effect. In order to gain further insight into the
mechanisms behind the differences in antago-miR-24-3p-EV
and pre-miR-214-3p-EV in vivo effects, miR cargo was ana-
lyzed and their fold change is reported in Supplementary
Table 3 and 4. Figure 7a, b shows how up-upregulated and
downregulated miRs are distributed. It is worth noting that
antago-miR-24-3p-EVs were found to be enriched in miR-214-
3p (Fig. 7a), while no changes in miR-24-3p content were
detected in pre-miR-214-3p-EVs (Fig. 7b). This finding is
consistent with the reduced β-catenin expression reported in
Fig. 4e, f. A cross-match of miRs, carried by different EVs, was
Fig. 5 miR-24-3p and miR-214-3p integrated interaction-networks
merge in c-myc a Network analysis between miR-24-3p/miR-214-3p
and mRNA targets. Lines represent interactions between genes and
miRs predicted by the IPA Software: indirect interactions (dotted
lines), direct interactions (continuous lines). b TECs treated as
indicated were lysed and analyzed for c-myc content, normalized to
β-actin content (n= 5) (**p< 0.01, none and EVs vs anti-IL-3R-
EVs, antago-miR-24-3p-EVs and pre-miR-214-3p-EVs, one-way
ANOVA)
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also performed. As shown in the Venn diagram (Fig. 7c), 4
miRs were downregulated in pre-miR214-3p-EVs, antago-miR-
24-3p-EVs and in anti-IL-3R-EVs (Fig. 7c). While the Venn
diagram in Fig. 7d shows the cross-match of upregulated miRs
shared by different EVs, only miR-214-3p was upregulated in
all EVs. DIANA miR path software was therefore interrogated
to identify the most relevant pathways which, along with Wnt-
β-catenin, may contribute to the overlapping of the anti-
angiogenic effects detected in antago-miR-24-3p-, pre-miR214-
3p-, and anti-IL-3R-EV-treated animals (Fig. 6b). In particular,
pathways correlating with downregulated miRs shared by anti-
IL-3R-EVs, pre-miR-214-3p-EVs and antago-miR-24-3p-EVs,
or by anti-IL-3R-EVs and pre-miR-214-3p-EVs, or anti-IL-3R-
EVs and antago-miR-24-3p-EVs were analyzed. As shown in
Fig. 8a and resumed in Fig. 8b, miR-222-3p, miR-16-5p, miR-
484, miR-17-5p, miR-106a-5p, miR-365b-5p, miR-196b-5p,
miR-19b-3p, miR-197-3p, and miR-193b-3p significantly cor-
related with at least 2 of the following pathways: pathway in
cancer, adherens junction, p53 signaling pathway, cell cycle
and ECM receptor interaction; whereas, miR-518d-5p and miR-
191-5p did not. Of note, miR-16-5p, commonly shared by pre-
miR-214-3p-EVs, antago-miR-24-3p-EVs, and anti-IL-3R-EVs
significantly correlated with 4 of the above pathways. Such
significant correlation was also found for miR-17-5p (in pre-
miR-214-3p-EVs) and miR-193b-3p (in antago-miR-24-3p-
EVs).
Discussion
The microenvironment is a complex and dynamic tissue in
tumor. It contains neoplastic and resident cells, including
stroma and vascular cells [43]. A host of soluble factors
have been widely found to modulate this environment. We
have previously shown that IL-3 can promote EC pro-
liferation and in vivo angiogenesis [44]. Moreover, it has
been shown that signals emanated by IL-3, released by
tumor infiltrating T-cells, promote in vivo tumor expansion
by increasing tumor neovascularization [3, 45]. However,
intercellular crosstalk can also occur in the tumor micro-
environment via direct cell-to-cell contact or via mediators
that have secreted into the extracellular environment [13].
EVs have become recognized as an important part of cel-
lular communication between cancer cells and cells within
the tumor microenvironment [14, 20, 46]. It is becoming
evident that EV-mediated communication has a major
Fig. 6 Effects of antago-miR-24-3p-EVs and pre-miR-214-3p-EVs on
TEC-derived vessels a, b Representative images of an in vivo
angiogenesis assay of TECs treated with antago-miR-24-3p-EVs and
pre-miR-214-3p-EVs either alone or in combination. Untreated TECs
and TECs treated with EVs and anti-IL-3R-EVs were also reported.
Data are reported in the histogram as number± SD of vessels per
sample (***p< 0.001, none and EVs vs others experimental condi-
tions; **p< 0.01, anti-IL-3R-EVs vs pre-miR-214-3p-EVs and pre-
miR-214-3p-EVs vs antago-miR-24-3p-EVs+ pre-miR-214-3p-EVs,
one-way ANOVA) (20× magnification). Scale bars indicate 50 μm
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influence on many aspects of tumor growth and progression
[13, 14, 19]. Indeed, EVs released from cancer cells, from
stroma and vascular cells can promote tumor growth even
by inducing tumor angiogenesis [14–16, 18].
TECs diverge from their normal counterpart at the
molecular and functional level [12]. In fact, TECs show
rapid turnover and express embryonic gene and vessel
growth regulating molecules [12]. Moreover, TECs derived
from differing tissues, including breast and kidney tumors,
produce IL-3 and are dependent on IL-3 for their growth
[10, 12]. We provide a proof of concept, in the present
study, for the proangiogenic properties of TEC-derived EVs
as well. This observation indicates that, as in normal ECs
exposed to inflammatory stimuli [22], EVs released by
TECs can act locally as paracrine proangiogenic mediators.
An anti-IL-3R blocking antibody [36] was therefore used to
investigate whether IL-3R blockade can be therapeutically
effective in preventing and/or impairing the growth of
tumor vessels that have already formed by interfering with
TEC-derived EVs. This may well be quite significant as an
efficient blood supply is required for cancer cells to grow
beyond a critical mass and progress to a malignant
Fig. 7 miR distribution in antago-miR-24-3p-EVs and pre-miR-214-
3p-EVs. a Dot plot distribution graph of the 15 modulated miRs in
antago-miR-24-3p-EVs compared to EVs. Dots represent fold change
values for each miR. miR-214-3p (red dot) was found to be sig-
nificantly upregulated in antago-miR-24-3p EVs (foldchange: 3.80±
1.00). b Dot plot distribution graph of the 21 modulated miRs in pre-
miR-214-3p-EVs compared to EVs. miR-24-3p (red dot) was found to
be almost unmodulated in pre-miR-214-3p-EVs (foldchange: 0.26±
0.14). c Venn diagram of downregulated miRs, identified in anti-IL-
3R-EVs, antago-miR-24-3p EVs and pre-miR-214-3p EVs, are
reported. The diagram shows an overlap of common miRs across
different EVs d Venn diagram of upregulated miRs identified in anti-
IL-3R-EVs, antago-miR-24-3p EVs and pre-miR-214-3p EVs. The
diagram shows an overlap of common miRs among different EVs
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phenotype [46, 47]. Indeed, we have proven that anti-IL-
3R-EVs, besides preventing the formation of tumor vessels
in vivo, are also able to impair the growth of TEC-derived
tumor vessels. EVs are known to influence the behavior of
other cells by transferring lipids, proteins, mRNAs, tran-
scription factors and miRs [13, 15, 37–39]. This behavior
suggests that IL-3R blockade somehow alters EV biological
activity by changing their cargo. Genome-wide profiling has
revealed that miRs are frequently abnormally expressed in
human cancers [48, 49]. Moreover, it is known that miRs
are involved in tumorigenesis, metastasis, chemo-resistance
and angiogenesis [48–51]. TEC-derived EVs were therefore
analyzed for their miR cargo. Indeed, a number of modu-
lated miRs, as compared to naive EVs, were found in anti-
IL-3R-EVs. There is an ever increasing amount of evidence
to suggest that miRs could work differentially in human
tumors. In fact, context-dependent and target-dependent
miR function has been reported [52]. Analyses of the
pathways associated with anti-IL-3R-EV-miR expression/
modulation have led us to the idea that some may poten-
tially play a critical role in our model. Attention was
focused on miRs involved in the regulation of the Wnt/β-
catenin signaling pathway in order to identify a crucial and
less complex network of miRs working in combination. The
canonical Wnt/β-catenin pathway can be positively or
negatively regulated by miRs at multiple levels [24, 27]. As
shown in this study, a number of miRs carried by anti-IL-
3R-EVs are able to target the Wnt/β-catenin pathway [24,
27]. Two of these, miR-214-3p, which directly targets β-
catenin [40], and miR-24-3p, which targets two members of
the “β-catenin interacting complex” (APC and GSK3β) [41]
were chosen for the study. The “destruction complex”
controls the stability of cytoplasmic β-catenin. When the
Wnt pathway is not engaged, CK1 and GSK3β phosphor-
ylate Axin-bound β-catenin to drive β-catenin to the pro-
teasome for disruption. In this study, we demonstrate that
APC and GSK3β as well as S33-S37-phosphorylated β-
catenin content increased in TECs as the result of anti-IL-
3R-EV treatment. Such specific phosphorylated sequence
element, at the N-terminal domain of β-catenin, corresponds
to the consensus β-TrCP recognition site required for SCF
β-TrCP E3 ubiquitin ligase-mediated degradation [53–55].
We herein provided evidences for the formation of a pβ-
catenin/β-TrCP complex as the result of anti-IL-3R-EV
treatment. Moreover, it is demonstrated that the effects of
anti-IL-3R-EVs may be recapitulated by transfecting cells
with antago-miR-24-3p-EVs or using EVs that are depleted
of miR-24-3p to stimulate TECs. Furthermore, the trans-
fection of TECs with pre-miR-214-3p and the treatment of
TECs with EVs that over-express miR-214-3p led to a
reduction in β-catenin content. The same effects were
observed upon anti-IL-3R-EV treatment. β-catenin, in the
nucleus, functions as a transcription factor to activate the
expression of cell proliferation, migration and survival
genes, such as c-myc and cyclin D1 [29, 32–34]. c-myc was
found to be upregulated in naive EV-treated TECs, whereas
it was downregulated in TECs stimulated with anti-IL-3R-
EVs, antago-miR-24-3p-EVs and pre-miR-214-3p-EVs,
which is consistent with what is known on the integrated
miR-24-3p and miR-214-3p interaction-network. c-myc is
involved in the regulation of proliferation, growth, differ-
entiation and cell survival. It also plays a role in vascular
maturation and stabilization, as it is involved in vasculo-
genesis and angiogenesis [56–58]. c-myc has often been
found to be deregulated and/or overexpressed in trans-
formed cells. Our findings suggest that EVs may contribute
to c-myc deregulation, even in tumor vessels, via epigenetic
mechanisms that target the Wnt/β-catenin pathway.
The growing amount of information available on the
Wnt/miRs regulatory network points to the existence of a
complex circuit in cancer cells [24, 25, 30]. An analysis of
the modulated miRs in anti-IL-3R-EVs uncovered many
predictable miRs which post-transcriptionally control the
Wnt/β-catenin pathway at different levels, including miR-
200a, miR-126, miR-130 and many others [24, 25, 27, 30,
59, 60]. Although we cannot exclude the possibility that
EV inducing effects may depend largely on the combina-
tion of all the miRs taken together, a comparison of the
miR carried by antago-miR-24-3p-EVs, pre-miR-214-3p-
EVs, anti-IL-3R-EVs and their functional activity would
appear to point to the crucial role played by selective
enrichment pathways. As a matter of fact, antago-miR-24-
3p-EVs, which were enriched in miR-214-3p, were also
much more effective in their anti-angiogenic action than
pre-miR-214-3p-EVs. Moreover, a further and deeper
comparison among pre-miR-214-3p-EV, antago-miR-24-
3p-EV and anti-IL-3R-EV miR content led us to hypo-
thesize that their overlapping anti-angiogenic effects might
also depend on the combined action of a pattern of shared
miRs (miR-222-3p, miR-16-5p, miR-484 for all EV sam-
ples; miR-19b-3p miR-17-5p, miR-196b-5p, miR-365b-5p
for pre-miR-214-3p-EVs and anti-IL-3R-EVs; miR-106a-
5p, miR-197-3p, miR-193b-3p for antago-miR-24-3p-EVs
and anti-IL-3R-EVs) which may be involved in the
Fig. 8 miR/pathway heat map representation and KEGG pathways—
miRNA network. a Meta-analysis algorithm of the most significant path-
ways targeted by miR-222-3p, miR-16-5p, miR-484, miR-17-5p, miR-
106a-5p, miR-365b-5p, miR-196b-5p, miR-19b-3p, miR-197-3p, miR-
193b-3p, miR-518d-5p and miR-191-5p. Relevant correlation with the
following pathways was found; cell cycle pathway (p-value= 9.55−11),
adherens junction (p-value= 1.0−325), pathway in cancer (p-value= 1.9−8),
ECM receptor interaction (p-value= 1.0−325) and p53 signaling pathway
(p-value= 1.27−8). (Image from DIANA-miRpath software). Color nota-
tion identifies Log (p-value). b Representative scheme of DIANA miRpath
analysis between miRs and correlated pathways. miRs were linked with
pathways by lines of different colors. Red lines: miRs involved in 4
pathways; yellow lines: miRs involved in 3 pathways; green lines: miRs
involved in two pathways
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regulation of a network of genes related to cancer devel-
opment/progression. Moreover, we found that miR-16-5p,
commonly shared by pre-miR-214-3p-EVs, antago-miR-
24-3p-EVs, and in anti-IL-3R-EVs significantly correlated
with 4 out of the 5 pathways identified by DIANA miR
path software. Finally, our results suggest that miR-24-3p
may be involved in the reverse epigenetic silencing of
miR-214-3p, which moves to EVs from cells. Therefore,
besides supporting the notion that silencing or deleting
miRs widely modifies the cellular miR network, our results
also raise additional concerns about using antago-miRs as
therapeutics [61].
The transfer of EV-miR cargo into recipient cells is a
potent mechanism that can support cancer cell survival and/
or promote angiogenesis [14, 20, 49] We herein provide
evidence to show that, just like tumor cells, EVs released
from TECs acquire unique miR-cargo features which
account for their paracrine mechanism of action. We also
identify the Wnt/β-catenin pathway as a crucial regulator of
TEC-derived EV proangiogenic action. Moreover, our data
indicate that the IL-3R blockade may be a pharmacological
option that interferes with TEC-derived EV proangiogenic
action. Finally, there is clear interest in combining miR
therapeutics, delivered by small-carriers with conventional
cytotoxic agents, and molecularly targeted drugs [61]. The
IL-3R blockade may have the advantage of combining
standard-of-care treatments with an already established and
efficient EV-miR package which can enhance antitumor
effects.
Materials and methods
Reagents
A detailed list of reagents and antibodies is reported in
Supplementary Table 5.
Cell culture
Human breast-derived TECs were isolated and grown as
previously described [12, 62, 63]. In selected experiments,
starved TECs were cultured (24 h) in the presence of EVs,
anti-IL-3R-EVs or EVs that had either been depleted or
enriched with miRs (7× 103 EVs/target cell) [22]. Untreated
TECs served as controls. A Limulus amebocyte assay (con-
centration< 0.1 ng/ml) (Charles River Laboratories, Inc.,
Wilmington, MA, USA) was used to test possible con-
tamination. Details are in Supplementary Information.
All experiments were performed in accordance with
European Guidelines and policies and approved by the
Ethical Committee of the University of Turin.
Isolation and quantification of TEC-derived EVs
EVs were collected from EBM-cultured TECs which were
starved and FCS deprived for 24 h. To obtain IL-3R blockade
an anti-IL-3Rα neutralizing antibody (R&D Systems, Min-
neapolis, MN, USA) was used. Trypan blue was used to
evaluate cell viability at the end of each experiment (95± 3%
viable cells/experiment) [17, 37]. After a first centrifugation,
cell-free supernatants were submitted to differential ultra-
centrifugation. EV protein content was quantified as pre-
viously described [17]. A Limulus amebocyte assay
(concentration< 0.1 ng/ml) was also used. EV size distribu-
tion analyses were performed using a NanoSight LM10
(NanoSight Ltd, Minton Park, UK) [64]. Results were dis-
played as previously described [64]. EVs were also collected
for loss- or gain-of-function experiments, as described below.
Details are in Supplementary Information.
EV internalization by TECs
Confocal microscopy (LSM5-PASCAL; Zeiss, Oberko-
chen, Germany) was used to evaluate EV internalization.
Red fluorescent PKH26 dye was used to label a pool of EV
particles. Such labeled EVs were processed as previously
described [22]. On the basis of our preliminary results 7×
103 EV/target/cell concentration, were used. Details are
in Supplementary Information.
Cell proliferation assay
The proliferative activity of TECs, treated as indicated, was
assayed as previously described (number ± SD of cells per
field, 10× magnification) [12, 17, 65].
Western blot and co-immunoprecipitation analysis
TECs and TEC-derived EVs were lysed and protein con-
centrations obtained as previously described [22, 66, 67].
50 μg protein for cells and 10 μg for EVs were processed as
previously described [65]. In selected experiments protein-
A-Sepharose beads were used for co-immunoprecipitation
experiments [67]. Protein levels were normalized to β-actin
[68] or Histone-3 (H3). To evaluate β-catenin activity,
cytoplasmic and nuclear extracts [67] from TECs, either
treated or left untreated as indicated, were prepared as ori-
ginally described [69]. The presence of the anti-IL-3R
antibody bound to TEC-derived EVs or retained in the EV-
depleted CM, was also investigated by using an anti-mouse
IgG. To this end EVs recovered from 100k g ultra-
centrifugation were directly subjected to Western blot ana-
lysis, while the supernatants were additionally
ultracentrifuged for 24 h at 100 kg to obtain EV-depleted
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CM. These CM were 50× concentrated and analyzed by
western blot.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from TECs, either treated or left
untreated as indicated [17]. RNA, from cells and EVs, was
then retro-transcribed using TaqMan microRNA RT kits,
specific for miR-214-3p and miR-24-3p, and subjected to
quantitative real-time PCR (qRT–PCR) [64]. The small
nuclear RNA, RNU6B was used to normalize miR expression.
In order to collect EVs, depleted of miR-24-3p or enriched in
miR-214-3p, loss-of-function and gain-of-function experi-
ments were performed in TECs, as previously described [22,
64]. Details are in Supplementary Information.
miR screening
TEC-derived EVs, anti-IL-3R-EVs, antago-miR-24-3p-EVs
and pre-miR-214-3p-EVs (triplicate of 3 different prepara-
tions per sample) were analyzed for their miR content by
qRT–PCR using the Applied Biosystems TaqManH Micro-
RNA Assay Human Panel Early Access kit (Life Technol-
ogies). The expression profile of 375 human mature miRs
was examined via reverse transcription (Megaplex RT Pools;
Life Technologies) using an Applied Biosystems 7900H
qRT–PCR instrument, as previously described [70]. Raw Ct
values obtained by qRT–PCR were calculated using the SDS
software version 2.3. A comparison of miR expression was
conducted using the Expression Suite software (Life Tech-
nologies). Fold change in miR expression, across all samples,
was calculated as 2−ΔΔCt using basal EVs as control and by
normalizing the data using global normalization [71]. The
expression of miRs of interest in the analysis was confirmed
using the TaqMan microR specific assay kit (Applied Bio-
systems, Foster City, CA, USA), as described below. Details
are in Supplementary Information.
Tube-like structure formation (in vitro angiogenesis
assay)
Growth factor-reduced Matrigel matrix was used to evaluate
tube-like structure formation in TECs that were either treated
with EVs, anti-IL-3R-EVs (7× 103 EV/target cell, which was
found effective in preliminary experiments performed with
different EV numbers ranging from 5× 103 to 1× 104) or left
untreated [72]. The number of tube-like structures formed was
evaluated as detailed in Supplementary Information.
Study approval
Animal studies were conducted in accordance with the
Italian National Institute of Health Guide for the Care and
Use of Laboratory Animals (protocol no: 944/2015-PR).
Mice were housed according to the Federation of European
Laboratory Animal Science Association Guidelines and the
Ethical Committee of the University of Turin. All experi-
ments were performed in accordance with relevant guide-
lines and regulations.
In vivo angiogenesis assay
To evaluate the in vivo angiogenic potential of TEC-derived
EVs, 8 weeks old male SCID mice (Charles River
Laboratories Italia Srl, Calco, Italy) (randomized in three
groups; eight mice/each group) were injected s.c. into the
flank with a growth factor-reduced Matrigel matrix con-
taining 1× 106 TECs and 1× 105/cell of different EVs or
saline. The number of EVs was selected from preliminary
results obtained by using 0.5× 105/cell, 1× 105/cell, and
2× 105/cell (data not shown). Since no differences were
detected between 1× 105/cell and 2× 105/cell the lower
doses was used. Matrigel plugs were removed and
processed on day 7 after injection. In order to evaluate the
in vivo ability of EVs to induce vessel regression, TEC-
derived EVs or anti-IL-3R-EVs, or alternatively antago-
miR-24-3p-EVs or pre-miR-214-3p-EVs alone or in
combination (1× 105/injected cell), re-suspended in 20 μl
of saline, were directly injected into the Matrigel plugs of
SCID mice (randomized in 3 or 6 groups; 8 mice/each
group) on days 3 and 7 after TEC implantation (1× 106
cells). An equal volume of saline was used in control mice.
Matrigel plugs were removed and processed after 10 days
[12, 72]. Details are in Supplementary Information.
Bioinformatic analyses
Ingenuity Pathway Analysis (IPA) Software (Ingenuity
Systems, Qiagen, Redwood City, CA) was used to generate
the interaction-network that correlated the miRs of interest
and mRNAs.
The DIANA-miRPath v3.0 database was interrogated by
setting up KEGG annotations to select miR targeting
pathways, according to their enrichment in p-values. Each
miR and interaction dataset were entered and examined
individually or together with other significant miRs. The
merging algorithm was considered where appropriate [73].
Statistical analysis
All data are reported as mean± SD. The
D’Agostino–Pearson test was used to test normality.
Unpaired student t-tests were used to compare two experi-
mental groups, while one-way ANOVA, followed by
Tukey’s multiple comparison test, to compare ≥ 3 experi-
mental groups. The differences in the fold induction of
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protein contents were evaluated by densitometric analyses
and reported as relative amount. For the in vitro experi-
ments the minimum sample size to ensure 90% power
between controls and experimental groups with a prob-
ability level of 0.05, two-tailed hypothesis, was three
experiments performed in triplicate. For the in vivo
experiments the minimum sample size to detect a 40%
difference between controls and experimental groups, with
90% power and a probability level of 0.05 in a two-tailed
hypothesis, was n= 8 mice/group. P-values< 0.05 were
considered statistically significant (*p< 0.05, **p< 0.01,
***p< 0.001). Three independent and blinded investigators
evaluated the in vivo outcomes. All statistical analyses were
carried out using GraphPad Prism version 5.04 (GraphPad
Software, Inc., La Jolla, CA, USA).
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